TACR1, tachykinin receptor 1, 6869

N. diseases: 217; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.320 GeneticVariation group BEFREE To further elucidate the role of TACR1 in affective disorders, rs3771829 was genotyped in a second BPAD sample of 593 subjects (UCL2), in 997 subjects with ADS, and a subsample of 143 individuals diagnosed with BPAD and comorbid alcohol dependence (BPALC). rs3771829 was associated with BPAD (UCL1 and UCL2 combined: P = 2.0 × 10(-3)), ADS (P = 2.0 × 10(-3)) and BPALC (P = 6.0 × 10(-4)) compared with controls screened for the absence of mental illness and alcohol dependence. 24817687 2014
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.320 Biomarker group PSYGENET The association with TACR1 and BPAD, ADS, and ADHD suggests a shared molecular pathophysiology between these affective disorders. 24817687 2014
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.320 Biomarker group PSYGENET Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder. 19415819 2009
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.320 Biomarker group PSYGENET It also discusses the promise of substance P-receptor antagonists (SPA) for the treatment of affective disorders and their proposed mechanism of action. 12692775 2003
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.320 Biomarker group BEFREE It also discusses the promise of substance P-receptor antagonists (SPA) for the treatment of affective disorders and their proposed mechanism of action. 12692775 2003
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.320 Biomarker group PSYGENET More recently, the neuropeptide substance P (SP) and its receptor (the neurokinin-1 receptor [NK1R]) have been implicated in the pathophysiology of affective disorders, including depression. 12562138 2002
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.320 Biomarker group PSYGENET These observations suggest that centrally-acting NK(1) receptor antagonists may have clinical utility in the treatment of a range of anxiety and mood disorders. 10818257 2000